{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T19:58:19Z","timestamp":1649015899351},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/maj.0b013e3182513fb4","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T19:45:46Z","timestamp":1335383146000},"page":"345-349","source":"Crossref","is-referenced-by-count":0,"title":["Imaging and Clinical Measurements"],"prefix":"10.1016","volume":"343","author":[{"given":"Carlos","family":"Pineda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0005","first-page":"2225","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group","volume":"24","author":"van der Heijde","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASsessment in AS\u201d international working group; European League Against Rheumatism. ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0020","first-page":"1003","article-title":"Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0025","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0035","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0050","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","article-title":"Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jbspin.2010.07.008","article-title":"Role for imaging studies in ankylosing spondylitis","volume":"78","author":"Chary-Valckenaere","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0060","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0070","first-page":"948","article-title":"Clinimetric concepts in outcome assessment: the OMERACT filter","volume":"26","author":"Bellamy","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.59.2.135","article-title":"Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis\u2014cellularity correlates with the degree of enhancement detected by magnetic resonance imaging","volume":"59","author":"Bollow","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0080","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.10883","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/rheumatology\/kei046","article-title":"Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumor necrosis factor agent infliximab","volume":"44","author":"Sieper","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0090","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","article-title":"Low-dose infliximab (3 mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0095","first-page":"2030","article-title":"et al; M03\u2013606 Study Group. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis","volume":"35","author":"Maksymowych","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0100","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with tumor necrosis factor alpha receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0110","first-page":"980","article-title":"Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0115","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumor necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0125","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"61","author":"de Vries","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0135","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0140","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0145","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Canadian (M03\u2013606) Study Group; ATLAS Study Group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0150","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0155","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/rheumatology\/keh713","article-title":"The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis","volume":"44","author":"Barkham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0160","first-page":"79","article-title":"Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies","volume":"33","author":"Cohen","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/art.22469","article-title":"Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis","volume":"57","author":"Maksymowych","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e3182513fb4_bb0170","first-page":"521","article-title":"How much inflammation do patients with axial spondyloarthritis have who report low levels of disease activity? A prospective cohort study","volume":"70","author":"Kiltz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0175","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e3182513fb4_bb0180","first-page":"631","article-title":"A substantial proportion of AS patients respond to TNF inhibitors despite not fulfilling the criteria for initiating anti-TNF therapy according to the ASAS\/EULAR recommendations","volume":"68","author":"Heiberg","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/ard.2008.100826","article-title":"Assessment of Spondylo-Arthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0190","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","article-title":"Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors","volume":"69","author":"Pedersen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0195","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","article-title":"The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-a inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China","volume":"50","author":"Xu","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0200","first-page":"2273","article-title":"Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada","volume":"34","author":"Maksymowych","year":"2007","journal-title":"The Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0205","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/acr.20312","article-title":"Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondyloarthritis","volume":"62","author":"Weber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0210","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182513fb4_bb0215","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension of up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rehum"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T16:25:57Z","timestamp":1542990357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915309605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0002962915309605"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182513fb4","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}